|
| Press Releases |
|
 |
|
| Friday, May 29, 2020 |
|
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
| The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
| Monday, May 18, 2020 |
|
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
| Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
| Thursday, May 14, 2020 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
| Thursday, March 26, 2020 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
| Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
| Wednesday, March 25, 2020 |
|
|
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ. more info >> |
|
| Monday, March 23, 2020 |
|
|
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health) |
| Eisai Co., Ltd. announced today that it will launch "NouKNOWTM", a new digital tool (non-medical device) for self-assessment of brain performance (brain health). more info >> |
|
| Thursday, March 19, 2020 |
|
|
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan |
| EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families. more info >> |
|
| Tuesday, February 25, 2020 |
|
|
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China |
| Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App
Dec 27, 2024 22:30 HKT/SGT
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 27, 2024 15:20 HKT/SGT
|
|
|
Gruelling Challenge Awaits TGR In Saudi Arabia 
Dec 27, 2024 15:20 JST
|
|
|
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
|
|
|
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 9:36 JST
|
|
|
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Dec 27, 2024 06:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
|
|
|
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
|
|
|
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
|
|
|
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 9:47 JST
|
|
|
Caj Africa Releases Analytical Report on Syria's 2024 Socialist Dynamics
Dec 26, 2024 07:00 HKT/SGT
|
|
|
Spectral Capital Announces Transformation into a Deep Quantum Technology Platform
Dec 25, 2024 10:59 HKT/SGT
|
|
|
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
|
|
|
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
|
|
|
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
